This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Case Reports

. 2007 Jan;29(1):220-1.

doi: 10.1183/09031936.00110006.

PDE-5 inhibitors lower portal and pulmonary pressure in portopulmonary hypertension

P Deibert, H Bremer, M Roessle, A-K Kurz-Schmieg, W Kreisel

PMID: 17197488
DOI: 10.1183/09031936.00110006

Free article

Case Reports

PDE-5 inhibitors lower portal and pulmonary pressure in portopulmonary hypertension

P Deibert et al. Eur Respir J. 2007 Jan.

Free article

. 2007 Jan;29(1):220-1.

doi: 10.1183/09031936.00110006.

Authors

P Deibert, H Bremer, M Roessle, A-K Kurz-Schmieg, W Kreisel

PMID: 17197488
DOI: 10.1183/09031936.00110006

No abstract available

PubMed Disclaimer

Comment on

Sildenafil treatment for portopulmonary hypertension.
Reichenberger F, Voswinckel R, Steveling E, Enke B, Kreckel A, Olschewski H, Grimminger F, Seeger W, Ghofrani HA. Reichenberger F, et al. Eur Respir J. 2006 Sep;28(3):563-7. doi: 10.1183/09031936.06.00030206. Epub 2006 Jun 28. Eur Respir J. 2006. PMID: 16807265 Clinical Trial.

Similar articles

Tadalafil as treatment for idiopathic pulmonary arterial hypertension.
de Carvalho AC, Hovnanian AL, Fernandes CJ, Lapa M, Jardim C, Souza R. de Carvalho AC, et al. Arq Bras Cardiol. 2006 Nov;87(5):e195-7. doi: 10.1590/s0066-782x2006001800027. Arq Bras Cardiol. 2006. PMID: 17396193 English, Portuguese.
[Treatment of pulmonary arterial hypertension: phosphodiesterase-5 inhibitors].
Ghofrani HA, Grimminger F. Ghofrani HA, et al. Dtsch Med Wochenschr. 2006 Dec 8;131(49 Suppl 9):S311-4. doi: 10.1055/s-2006-957199. Dtsch Med Wochenschr. 2006. PMID: 17139594 Review. German.
Sildenafil in pulmonary hypertension.
Nanivadekar A. Nanivadekar A. Indian Heart J. 2003 May-Jun;55(3):285; author reply 285. Indian Heart J. 2003. PMID: 14560947 No abstract available.
Type 5 phosphodiesterase inhibitors in the treatment of erectile dysfunction and cardiovascular disease.
Ravipati G, McClung JA, Aronow WS, Peterson SJ, Frishman WH. Ravipati G, et al. Cardiol Rev. 2007 Mar-Apr;15(2):76-86. doi: 10.1097/01.crd.0000233904.77128.49. Cardiol Rev. 2007. PMID: 17303994 Review.
Sildenafil in primary pulmonary hypertension.
Prasad S, Wilkinson J, Gatzoulis MA. Prasad S, et al. N Engl J Med. 2000 Nov 2;343(18):1342. doi: 10.1056/NEJM200011023431814. N Engl J Med. 2000. PMID: 11183578 No abstract available.

See all similar articles

Cited by

Portopulmonary hypertension: Diagnosis, clinical features, and medical therapy.
Bartolome SD. Bartolome SD. Clin Liver Dis (Hoboken). 2014 Aug 25;4(2):42-45. doi: 10.1002/cld.401. eCollection 2014 Aug. Clin Liver Dis (Hoboken). 2014. PMID: 30992919 Free PMC article. No abstract available.
Treatment Barriers in Portopulmonary Hypertension.
AbuHalimeh B, Krowka MJ, Tonelli AR. AbuHalimeh B, et al. Hepatology. 2019 Jan;69(1):431-443. doi: 10.1002/hep.30197. Epub 2018 Dec 18. Hepatology. 2019. PMID: 30063259 Free PMC article. Review.
Phosphodiesterase-5 inhibitors have distinct effects on the hemodynamics of the liver.
Halverscheid L, Deibert P, Schmidt R, Blum HE, Dunkern T, Pannen BH, Kreisel W. Halverscheid L, et al. BMC Gastroenterol. 2009 Sep 18;9:69. doi: 10.1186/1471-230X-9-69. BMC Gastroenterol. 2009. PMID: 19765284 Free PMC article.
Tadalafil improves erectile dysfunction and quality of life in men with cirrhosis: a randomized double blind placebo controlled trial.
Jagdish RK, Kamaal A, Shasthry SM, Benjamin J, Maiwall R, Jindal A, Choudhary A, Rajan V, Arora V, Bhardwaj A, Kumar G, Kumar M, Sarin SK. Jagdish RK, et al. Hepatol Int. 2023 Apr;17(2):434-451. doi: 10.1007/s12072-021-10264-w. Epub 2021 Nov 14. Hepatol Int. 2023. PMID: 34775577 Clinical Trial.
Genetic risk factors for portopulmonary hypertension in patients with advanced liver disease.
Roberts KE, Fallon MB, Krowka MJ, Brown RS, Trotter JF, Peter I, Tighiouart H, Knowles JA, Rabinowitz D, Benza RL, Badesch DB, Taichman DB, Horn EM, Zacks S, Kaplowitz N, Kawut SM; Pulmonary Vascular Complications of Liver Disease Study Group. Roberts KE, et al. Am J Respir Crit Care Med. 2009 May 1;179(9):835-42. doi: 10.1164/rccm.200809-1472OC. Epub 2009 Feb 12. Am J Respir Crit Care Med. 2009. PMID: 19218192 Free PMC article.

See all "Cited by" articles

Publication types

Actions
Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- HighWire
Medical
- MedlinePlus Health Information